Materials and methods for extracellular vessicle-associated diseases
Sortilin is a sorting receptor that directs target proteins to the secretary or endocytic compartments of cells that is found in both extracellular vesicles and cells. Provided herein are methods and compositions for decreasing or inhibiting trafficking of sortilin to an extracellular vesicle, for example by inhibiting the formation of intermolecular sortilin dimers.
1. A method for identifying a test agent that modulates dimerization of sortilin, the method comprising:
(i) contacting a cell with a test agent, wherein the cell expresses a first sortilin polypeptide comprising a first label, and a second sortilin polypeptide comprising a second label, wherein the first and second sortilin polypeptide comprises independently the amino acid sequence of SEQ ID NO: 1; and
(ii) detecting a contact level between the first and second sortilin polypeptide expressed in the cell,
wherein a change in contact level relative to a control or reference level indicates the agent modulates dimerization of sortilin.
2. The method of claim 1 , wherein said detecting comprises analyzing the cell contacted in step (i) using Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET), and wherein a change in FRET signal relative to a control or reference level indicates the agent modulates dimerization of sortilin.
3. The method of claim 2 , wherein an increase in FRET signal relative to a control or reference level indicates the compound inhibits dimerization of sortilin.
4. The method of claim 2 , wherein a decrease in FRET signal relative to a control or reference level indicates the compound increases dimerization of sortilin.
5. The method of claim 2 , wherein the control or reference level is a FRET signal in a cell expressing either the first sortilin polypeptide or the second sortilin polypeptide.
6. The method of claim 2 , wherein said detecting comprises contacting the cell with a first ligand and a second ligand, wherein the first ligand is capable of binding with the first label and is conjugated with a with a Fluorescence Resonance Energy Transfer (FRET) donor, and wherein the second ligand is capable of binding with the second label and is conjugated with a FRET acceptor.
7. The method of claim 6 , wherein the first or second ligand is an antibody.
8. The method of claim 1 , wherein the agent inhibits dimerization of sortilin.
9. The method of claim 1 , wherein the agent increases dimerization of sortilin.